Funding restrictions for rituximab and eltrombopag widened in New Zealand
New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of proposals to widen the restriction on rituximab use in DHB hospitals and expand the funding of eltrombopag in both hospitals and the community. This was the subject of consultation letters in September and November 2013 respectively.
In summary, the effects of the decisions are that:
- The restriction on the use in hospitals of rituximab, Swiss drug major Roche’s (ROG: SIX) Rituxan, will be widened to include nine new indications; and
- The funding for eltrombopag, UK pharma giant GlaxoSmithKline’s (LSE: GSK) Promacta, will be widened to include patients with 20,000 to 30,000 platelets per microliter and evidence of significant mucocutaneous bleeding.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze